AstraZeneca announced plans to invest $2 billion to expand its long-standing manufacturing footprint in Maryland, including a significant expansion of its flagship biologics facility in Frederick and construction of a new state-of-the-art facility in Gaithersburg for clinical supply of molecules
On November 21st 2025 Eli Lilly became the first pharmaceutical company to reach a $1 trillion market valuation this week, worth more than twice the value of any other drugmaker. The company’s stock has soared on the back of the
Novartis has announced plans to expand its operations in North Carolina with the creation of a new flagship manufacturing hub. The investment forms part of the company’s five-year, $23 billion commitment to build end-to-end manufacturing capacity for its key medicines
Novartis has announced the opening of a new 10,000-square-foot radioligand therapy (RLT) manufacturing facility in Carlsbad, California. The new site is part of the company’s previously announced $23 billion investment in US infrastructure over the next five years. The facility,
Novo Nordisk and Pfizer have escalated their competing bids for obesity drug developer Metsera to approximately $10 billion, transforming what began as a straightforward acquisition into a high-stakes corporate battle marked by legal challenges and regulatory scrutiny. Metsera’s board declared
Eli Lilly and Company has announced plans to construct a new $3 billion manufacturing facility in Katwijk, the Netherlands, located within the Leiden Bio Science Park. The facility will expand Lilly’s global capacity to produce oral medicines and strengthen its
Eli Lilly and Company has announced plans to invest more than $1.2 billion to expand and modernise its Lilly del Caribe manufacturing site in Carolina, Puerto Rico. The investment will integrate advanced technologies and expand production capacity to support the
Lupin Limited, a global pharmaceutical company, has inaugurated its new corporate offices at 100 Somerset Corporate Blvd in Bridgewater, New Jersey. The move strengthens Lupin’s presence in the state, where it already operates manufacturing and research facilities in Somerset. The
Takeda Pharmaceutical Company has entered a global strategic partnership with China’s Innovent Biologics to acquire rights to two late-stage investigational oncology medicines and an option on an early-stage program, the companies announced October 22. Under the agreement, Takeda will pay
Merck, known as MSD outside the United States and Canada, has broken ground on a $3 billion pharmaceutical manufacturing facility at its Elkton, Virginia site. The 400,000-square-foot Center of Excellence for Pharmaceutical Manufacturing will expand the company’s small molecule manufacturing
